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Essentials
• Hypodysfibrinogenemia is rarely reported among the congenital fibrinogen disorders.
• This first systematic literature review led to identification of 51 hypodysfibrinogenemic cases.
• Diagnosis based only on functional/antigenic fibrinogen ratio may be insufficient.
• Family studies show an incomplete segregation of mutation with the clinical phenotypes.
Summary. Background: Hypodysfibrinogenemia is a rare disease characterized by decreased levels of a dysfunctional fibrinogen. It shares features with both hypo-and dysfibrinogenemia, although with specific molecular patterns and clinical phenotypes. Objectives: To better define the genetics, the diagnosis and the clinical features of hypodysfibrinogenemia. Patients/Methods: A systematic literature search led to 167 records. After removal of duplicates, abstract screening and full-text reviewing, 56 molecular and/or clinical studies were analyzed, including a novel FGB missense mutation in a woman with a mild bleeding phenotype. Results: A total of 32 single causative mutations were reported, mainly in the COOH-terminal region of the c or Aa chains at heterozygous or homozygous state. Seven additional hypodysfibrinogenemias were due to compound heterozygosity. The hypofibrinogenemic phenotypes were a result of an impaired assembly or secretion or an increased clearance of the fibrinogen variant, whereas the dysfibrinogenemic phenotype was mainly a result of a defective fibrin polymerization and an abnormal calcium or tPA binding. Among 51 identified index cases, a functional/antigenic fibrinogen ratio < 0.7 had a sensitivity of 86% for the diagnosis of hypodysfibrinogenemia. Eleven patients (22%) were asymptomatic at time of diagnosis, 23 (45%) had a mild bleeding phenotype with mainly obstetrical or gynecologic-related hemorrhage and 22 (43%) had experienced at least one thrombotic event, including 23 venous and eight arterial thromboses. Conclusions: This first systematic review on hypodysfibrinogenemia shows the heterogeneity of causative mutations and that misdiagnosis could occur in relation to the functional and antigenic fibrinogen levels. Family studies reveal an incomplete segregation of the mutation with the clinical phenotype.
Introduction
Congenital fibrinogen disorders are considered to be the third most frequent rare coagulation disorder [1] . They are caused by deficiency and/or defects in the fibrinogen molecule and are classified according to the amount of functional and antigenic fibrinogen values [2] . Quantitative disorders include hypofibrinogenemia and afibrinogenemia, characterized by decreased or absence of fibrinogen, respectively. Qualitative disorders are defined by normal quantity (i.e. dysfibrinogenemia) or decreased levels (i.e. hypodysfibrinogenemia) of a dysfunctional fibrinogen [2] .
Hypodysfibrinogenemia, which is the least frequently reported congenital fibrinogen disorder, shares features with both hypo-and dysfibrinogenemia: the decreased levels of circulating fibrinogen lead to the 'hypofibrinogenemic phenotype', whereas the dysfunction of the fibrinogen molecule is related to the 'dysfibrinogenemic phenotype' [3] . Usually, hypodysfibrinogenemia is considered and discussed together with hypo-or dysfibrinogenemia, even though specific causative mutations confer peculiar biological characteristics and clinical features. The exact incidence of hypodysfibrinogenemia is not known; it is sometimes misdiagnosed as hypofibrinogenemia, especially in the case of low antigenic fibrinogen levels [4] . Several molecular mechanisms leading to hypodysfibrinogenemia have been identified, including heterozygosity or compound heterozygosity for missense and/or nonsense mutations [5] . However, only a few have been clearly characterized by the expression of recombinant protein [6] . Several hypodysfibrinogenemic patients with severe bleeding or recurrent thrombosis have been reported [7, 8] , but the incidence of adverse outcomes is also poorly estimated.
Here, we report a new heterozygous missense mutation of Bb-chain identified in a young woman with a debatable mild bleeding phenotype. This case prompted us to carry out an extensive review, the first one performed on hypodysfibrinogenemia, in order to better define the genetic causes, the diagnosis and the clinical course of this rare disease.
Patient and methods

Case report
A 33-year-old Moroccan woman, with a history of Hashimoto's thyroiditis, was discussed at our consultation following the incidental finding of a low fibrinogen level at the end of her third pregnancy. Her obstetrical history was characterized by two successfull vaginal deliveries and one miscarriage followed by metrorrhagia lasting nearly 2 months. No other bleeding nor thrombotic symptoms were reported, even after two teeth extractions and a sclerotherapy of varicose veins. The complete hemostasis work-up showed decreased functional (Clauss method, 0.8 g L À1 ; normal range,
2-4 g L
À1
) and antigenic (1.5 g L À1 ; normal range, 2-4 g L À1 ) fibrinogen levels with a functional/antigenic ratio of 0.5 and prolonged reptilase and thrombin times, suggesting a hypodysfibrinogenemia (Table S1 ). Her asymptomatic 7-year-old son had a similar biological phenotype. Neither bleeding nor thrombotic tendency was detected in her four brothers, two sisters or her non-consanguineous parents. After informed consent, genetic screening of the three fibrinogen genes, FGA, FGB and FGG, was performed as previously described [9] . 
Results
Case report
Genetic analysis of the patient's genomic DNA revealed a heterozygous missense mutation in the fibrinogen Bbchain (nucleotide numbering based on the cDNA sequences from GenBank, entry #M64983): c.284 G>C (exon 2) p.Cys95Ser (p.Cys65Ser in the mature chain without the signal peptide). Her son, to date asymptomatic, was also heterozygous for the same mutation. A thorough search of the literature (initially 166 records, including 29 publications identified by manual review) revealed that this mutation, predicted to be deleterious by SIFT analysis, had not been identified before. The missense mutation affects a Cys residue involved in a disulfide bond with Cys36 in the mature Aa chain (Fig. 1 , Table 1 ). The loss of this inter-chain disulphide bond, by mutating either BbCys95 (Cys65) or AaCys55 (Cys36), has been shown in transfected cell models to impact the assembly of the two AaBbc trimer intermediates into the final fibrinogen hexamer before secretion [10, 11] , compatible with a hypofibrinogenemic phenotype. However, the hypodysfibrinogenemic phenotype of our patient indicates that the secretion defect is not complete and at least some of the mutant chain is found in the circulation. Interestingly, mutation of Aa Cys55 (Cys36) to Arg (Fibrinogen Marseille) or Gly (Fibrinogen La Seyne and Fibrinogen Quimper) also causes hypodysfibrinogenemia [12] ( Table 1 ). In the non-mutated fibrinogen hexamer, there are no free cysteine residues. Thus, for all these mutations affecting one residue of a Cys-Cys disulphide pair, the resulting free Cys residue may be implicated in disulphide bridging with Cys residues in other molecules, possibly contributing to the dysfibrinogenemic phenotype.
Systematic literature review
After removal of duplicate reports, titles and abstracts of 109 records were screened and 90 publications were selected for full-text review (Fig. 2) . Following exclusion of incomplete or misdiagnosed reports, we finally included 56 studies, eight providing only biological and clinical data, eight only molecular data and 40 both biological, clinical and molecular data. Three studies included more than one patient. Overall, 51 index cases with hypodysfibrinogenemia were identified and considered in the final analysis.
Molecular anomalies
A total of 32 single mutations were identified, 10 (31%) in FGA, five (16%) in FGB and 17 (53%) in FGG (Table 1) . Ten mutations were found clustered in the highly conserved COOH-terminal region of the c chain between residues Asn345 and Ala353 (Asn319-Ala327 in the mature chain). Four late-truncating mutations were reported in the COOH-terminal part of the Aa chain. Causative mutations were mainly missense mutations (n = 21, 66%), followed by nonsense (8, 12.5%) or frameshift (8, 12.5%) mutations. Seven patients were homozygous. The FGA Trp295X mutation in homozygosity was previously reported in an Algerian patient diagnosed as afibrinogenemic, although without details on the fibrinogen values [13] . Seven additional hypodysfibrinogenemia cases were a result of compound heterozygosity for mutations on the same or different fibrinogen genes [4, 8, [14] [15] [16] [17] [18] . Expression of recombinant fibrinogens was performed for seven fibrinogen variants [5] [6] [7] [18] [19] [20] [21] .
Fibrinogen levels
As reported in Table 2 , a total of 51 cases were identified. Functional and antigenic fibrinogen, assessed by several methods (i.e. Clauss, PT-derived, immunologic assays, heat precipitation, clottable protein, and physical fibrinogen concentration from fibrinopeptide quantification), was below the reference ranges. The mean functional and antigenic fibrinogen levels were 0.52 (range, 0.1-1.1) and 1.18 (0.31-1.8) g L À1 , respectively, with a mean ratio of fibrinogen functional activity/antigenic levels of 0.46 (0.07-1.25). Six (12%) patients had a ratio > 0.7, whereas fibrinogen functional or antigenic levels were not available in five cases; we assumed that these patients were suffering from hypodysfibrinogenemia according to the fibrinogen mutation or to the relatives' fibrinogen values [18, [22] [23] [24] [25] .
Clinical features
The mean age of diagnosis was 32 years (1-83). A total of 23 (45%) patients presented at least one bleeding episode at the time of diagnosis, including one spontaneous cerebral bleeding. Bleeding was frequent among child-bearing women, including post-partum hemorrhage (n = 7, 30%) and menometrorrhagia (n = 8, 34%), which explains why hypodysfibrinogenemia was reported more frequently in women (n = 33, 65%). In addition, seven (21%) women reported at least one miscarriage. Overall, 22 patients (44%) experienced 31 arterial (three central and five peripheral artery occlusions) and/or venous thromboses (10 deep venous thrombosis, nine pulmonary embolisms, two superficial venous thrombosis and two splanchnic venous thrombosis). The mean age of first thrombotic event was 30 years . Thrombotic recurrences were frequent (n = 11/22, 50%), mainly in the venous territory. Available data did not allow determination of whether these events occurred under an appropriate antithrombotic treatment, except for three cases: a young woman with recurrent venous thromboses under oral anticoagulation [26] , a man (Fibrinogen Freiburg I) with recurrent arterial thromboses under low-molecular-weight heparin and aspirin [14] and another man with recurrent extensive bilateral pulmonary embolisms and intracardiac thromboses despite therapeutic international normalized ratio (INR) [24] . Eleven patients (22%) were asymptomatic at time of diagnosis. Congenital fibrinogen disorders are classified according to the fibrinogen levels [3] . Usually, dysfibrinogenemia is suspected in the case of discrepancy between decreased fibrinogen activity and normal antigenic levels [27] , with a ratio ≤ 0.7 suggestive of dysfibrinogenemia [28, 29] . Hypodysfibrinogenemia is also suspected in the case of discrepancy between decreased fibrinogen functional activity and decreased antigenic levels, whereas hypofibrinogenemia is classically defined by similar decreased levels. In our study a ratio lower than 0.7 would have a sensitivity of 86%, suggesting that this cut-off could not allow recognition of all hypodysfibrinogenemic cases, especially when antigenic fibrinogen levels are very low. Additional tests may be necessary to distinguish between hypoand hypodysfibrinogenemia. Conventional procedures such as SDS-polyacrylamide gel electrophoresis, reverse phase high-performance liquid chromatography (HPLC) and traditional mass spectrometry (MS) can identify fibrinogen chain composition and therefore identify circulating fibrinogen variants [22, [30] [31] [32] . More recently, S.O. Brennan's group described the direct analysis of fibrinogen by HPLC time of flight MS [33, 34] . This technique provides a higher resolution, permitting the detection of very subtle molecular changes, as well as the quantification of expression levels of fibrinogen variants [33, 35] . The lack of expression of a mutated chain confirms the diagnosis of hypofibrinogenemia instead of hypodysfibrinogenemia [36] . MS analysis is also useful in hypofibrinogenemic cases for which posttranslational modification alters the fibrinogen function [37] (e.g. in fibrinogen storage disease, where the fibrinogen variant is not secreted but accumulates in hepatocytes, resulting in defective liver function and an acquired fibrinogen dysfunction as a result of abnormal sialylation) [38] . Genetic insight: hypo-and dysf-phenotypes Hypodysfibrinogenemia can be caused by several molecular mechanisms. On one hand, mutations can lead to a decreased assembly and/or secretion of an abnormal fibrinogen chain. Pulse-chase analysis of recombinant Suhl (Frostburg) and Cordoba Fibrinogen in CHO or COS-1 cells showed that the rate of both assembly and secretion were lower than that of normal fibrinogen [21, 39] . On the other hand, Fibrinogen Otsu I (Vlissingen, Frankfurt IV) and Okayama II were normally synthetized and assembled but only partially secreted [6] . Expression studies of recombinant protein are important to determine the reason of the 'hypofibrinogenemic' phenotype. However, it should be noted that recombinant fibrinogen levels in the medium of cultured mammalian cells, most often not of hepatic origin, cannot exactly reflect the fibrinogen concentration in plasma [40] . Another molecular mechanism is increased fibrinogen variant clearance from circulation, as described by Ikeda et al. for Fibrinogen Sumida [19] . In this case, expression studies showed that the fibrinogen variant was normally assembled and secreted but the degradation of recombinant fibrinogen was faster than that of normal control [19] . Finally, the presence of compound heterozygosity for two different mutations, with one mutation responsible for the fibrinogen deficiency, usually a null mutation in FGA or FGB [41] , and one mutation responsible for the abnormal function of the molecule [14, 15] can result in hypodysfibrinogenemia. It is also interesting to note that for some fibrinogen variants the hypodysfibrinogenemic phenotype is expressed only in the homozygous state [5, 22, 30, 42, 43] . Indeed, heterozygous relatives have normal or low normal fibrinogen levels, suggesting that the variant chain could be either degraded or outcompeted by the wild-type chain during the course of fibrinogen hexamer assembly [32] . Most hypodysfibrinogenemia mutations are clustered in the COOH-terminal part of FGA or FGG. Although homozygosity for early Aa truncations causes afibrinogenemia [41] , late Aa truncations escape the nonsensemediated decay pathway and can lead to the production of a truncated Aa chain. The COOH-terminal regions of the Bb-chain and c-chain are highly conserved globular structures that do not easily tolerate mutations [41] , whereas the COOH-terminal part of the Aa chain is a flexible moiety that can still be assembled and secreted even when mutated or truncated.
The dysfibrinogenemic characteristics were confirmed by functional analyses in purified or plasmatic systems, showing for most variants defective polymerization, defective calcium binding and/or hypofibrinolysis [6, 25, [44] [45] [46] . Other mutations have a different pathophysiology: the FGA Val39Asp mutation (Fibrinogen Canterbury) introduces an inappropriate protein cleavage sequence of the Aa chain, leading to removal of fibrinopeptide A before the fibrinogen molecule enters the circulation [47] . For Fibrinogen Montpellier II a 3-bp insertion in FGA intron 2 results in a-chains lacking knob 'A', which is essential for the early stages of fibrin polymerization [7] . Functional studies determining fibrin clot mechanical and structural properties are of interest to better define the patient's phenotype [27] . For example, in a small series of six women affected by dys-or hypodysfibrinogenemia Zhou et al. showed that some parameters in thromboelastography assays could predict the occurrence of obstetric complications in qualitative fibrinogen disorders [48] .
Clinical features: bleeding, thrombosis and obstetrical complications
Patients suffering from congenital fibrinogen disorders have a wide variety of symptoms ranging from major bleeding to thromboses [27] . Overall, in hypodysfibrinogenemia bleeding seems to be mainly mild to moderate although hemorrhagic symptoms could be exacerbated in child-bearing women and in the post-partum, as previously described for dysfibrinogenemic women [29] . The relative high frequency of miscarriages highlights the essential role played by fibrinogen in maintaining hemostasis at the maternal-fetal interface throughout the pregnancy. A recent comparison of clinical features in patients with dysfibrinogenemia and hypodysfibrinogenemia suggested that the latter are more prone to develop thrombosis [3] . Also in this series, we found a high incidence of thromboses, especially in very young patients [49, 50] . However, it is important to note that the family studies, although often incomplete, did not show a complete segregation of the mutation with the clinical phenotype even for mutations with a structural defect linked with an increased risk of thrombosis [23] . Most likely, the observed clinical consequences are not only a direct result of the mutation but also result from additional genetic and/or environmental factors [8] . Several thrombotic cases are related to abnormal fibrin clot structure resulting in impaired fibrinolysis. As shown for the Dusart syndrome, which is due to a well-known fibrinogen variant associated with impaired fibrinolysis and a thrombotic phenotype [51] , long-term anticoagulation is effective in decreasing the risk of recurrent thrombosis events. Treatment of hypodysfibrinogenemia is particularly challenging because physicians may have to deal with both a thrombotic and a bleeding risk [52] . In monitoring patients under vitamin K antagonists, it should be taken into account that the prothrombin time is prolonged by low levels of fibrinogen and therefore the INR can overestimate the real level of anticoagulation [23] .
In the case of venous thrombosis, our data suggest that long-term anticoagulation may be necessary in selected cases in view of the high rate of recurrence observed.
Study limitations
The first main limitation of our study is that only case reports and small series were included. This is because of the rarity of the condition investigated and at the present time our approach is probably the only one allowing the analysis of a large dataset of hypodysfibrinogenemia. The second limitation is the obvious risk of publication bias leading to publication of only symptomatic or exceptional cases without considering asymptomatic or less striking cases. In addition, the clinical data are often incomplete and without follow-up. In this respect, several cases initially classified as asymptomatic may in fact become symptomatic a few years later, as was observed for congenital dysfibrinogenemia [29] . The third limitation, as illustrated by our case, is that the bleeding severity related to this fibrinogen disorder could be overestimated. Often, the clinical case description is only partial, emphasizing the main bleeding symptom without taking into account previous hemostatic challenges. Classification of patients according to clinical bleeding episodes, relying on the location, the potential clinical impact and the spontaneity of bleeding as proposed by Peyvandi et al., is more accurate for determining the bleeding phenotype [53] . Potential concomitant more common coagulation disorders, such as von Willebrand disease or platelet defects, could also contribute to the bleeding phenotype but are rarely investigated in this setting. This is true also for thrombotic events that could be related to genetic (thrombophilia) and environmental factors that are often not reported. Finally, we focused the literature search only on hypodysfibrinogenemia. In view of diagnosis pitfalls and the not optimal sensitivity of the activity/functional fibrinogen ratio, we can consider that some cases have been misreported as hypofibrinogenemia and therefore have escaped the literature screening. Therefore, even though we have tried to perform the most accurate systemic literature review according to the PROBE standard, some hypodysfibrinogenemia cases could have been missed.
Conclusion
We took the opportunity of the identification of a novel missense mutation accounting for hypodysfibrinogenemia to perform an extensive review of the literature. This is the first systematic review on hypodysfibrinogenemia giving insight into the genetics and the clinical features of this rare disease, which is caused by a wide spectrum of molecular anomalies. A misdiagnosis of hypofibrinogenemia may be quite common in the absence of antigenic fibrinogen measurements and additional tests, including genotyping, are necessary to confirm the diagnosis. Thrombosis and obstetrical adverse outcomes are frequent and their management requires a multidisciplinary approach. The identification of new hypodysfibrinogenemia cases and their causative mutations will help to identify new residues and domains relevant for the secretion and function of fibrinogen and mechanisms accounting for its deficiency. Further studies, with a larger group of patients, should improve the identification of patients and their real risk of adverse outcomes.
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